A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research

Qing, Liangliang; Li, Qingchao; Yang, Yong; Xu, Wenbo; Dong, Zhilong

doi:10.1186/s12894-022-01067-8

Cited by 9 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies have suggested that BC is a highly immunogenic malignant tumor and that the TME is involved in BC progression and prognosis [ 35 , 36 , 37 ]. PD-L1, TMB, and microsatellite instability biomarkers were used to predict the efficacy of treatment [ 38 ]. Therefore, a powerful RBP gene signature should be explored and validated for the prediction of BC progression.…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

RBPs in the development and progression of bladder cancer (BC) remains unclear. Here, we elucidated the role of RBPs in predicting the survival of patients with BC. Clinical information and RNA sequencing data of the training and validation cohorts were downloaded from the Cancer Genome Atlas and Gene Expression Omnibus databases, respectively. Survival-related differentially expressed RBPs were identified using Cox regression analyses. A total of 113 upregulated and 54 downregulated RBPs were observed, with six showing prognostic values (AHNAK, MAP1B, LAMA2, P4HB, FASN, and GSDMB). In both the GSE32548 and GSE31684 datasets, patients with low-risk scores showed longer overall survival than those with high-risk scores. AHNAK, MAP1B, P4HB, and FASN expression were significantly upregulated in both BC tissues and cell lines. BC tissues from the high-risk group showed higher proportions of naïve CD4+ T cells, macrophages M0 and M2, and neutrophils and lower proportions of plasma cells, CD8+ T cells, and T-cell follicular helper compared to the low-risk group. AHNAK knockdown significantly inhibited the proliferation, invasion, and migration of BC cells in vitro and inhibited the formation and growth of subcutaneous tumors in vivo. We thus developed and functionally validated a novel six-RBP-based prognostic model for BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…A number of excellent reviews have been published in recent years that describe the role of mucins in cancer, to cite some of them [86][87][88][89][90][91][92][93][94][95][96][97][98][99][100]. Changes in the expression, distribution, and glycosylation of mucins have been well documented in several cancers, providing a rationale for exploring their use as both diagnostic and prognostic markers, as well as targets for the development of cancer therapies.…”

Section: The Role Of Mucin-type O-glycans In Bladder Cancermentioning

confidence: 99%

Altered Glycosylation in Progression and Management of Bladder Cancer

2023

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most common malignancy worldwide, with an estimated 573,000 new cases and 213,000 deaths in 2020. Available therapeutic approaches are still unable to reduce the incidence of BC metastasis and the high mortality rates of BC patients. Therefore, there is a need to deepen our understanding of the molecular mechanisms underlying BC progression to develop new diagnostic and therapeutic tools. One such mechanism is protein glycosylation. Numerous studies reported changes in glycan biosynthesis during neoplastic transformation, resulting in the appearance of the so-called tumor-associated carbohydrate antigens (TACAs) on the cell surface. TACAs affect a wide range of key biological processes, including tumor cell survival and proliferation, invasion and metastasis, induction of chronic inflammation, angiogenesis, immune evasion, and insensitivity to apoptosis. The purpose of this review is to summarize the current information on how altered glycosylation of bladder cancer cells promotes disease progression and to present the potential use of glycans for diagnostic and therapeutic purposes.

show abstract

“…76,77 This protein is upregulated in the breast, 78 colorectal, 79,80 gastric, 81,82 lung, 83 ovarian, 84,85 prostate, 86 pancreatic, 87 and bladder cancers. 77 Ablin. 94 This molecule weighs 33 kDa, and the glycoprotein structure ranges from 0 to 0.4 ng mL À1 .…”

Section: Mucin 1 Proteinmentioning

confidence: 99%

“…There are three distinct regions of the Mucin 1 protein (MUC1) protein: a cytoplasmic domain (containing 69 amino acids), a hydrophobic membrane‐spanning domain (containing 31 amino acids), and an extracellular domain with a sequence of 20‐amino acid repeats 76 . MUC1 has preservation activity and possibly contributes to cell signaling pathways related to cancer progression 76,77 . This protein is upregulated in the breast, 78 colorectal, 79,80 gastric, 81,82 lung, 83 ovarian, 84,85 prostate, 86 pancreatic, 87 and bladder cancers 77 .…”

Section: Qd‐apt Conjugates For Cancer Managementmentioning

confidence: 99%

“…MUC1 has preservation activity and possibly contributes to cell signaling pathways related to cancer progression 76,77 . This protein is upregulated in the breast, 78 colorectal, 79,80 gastric, 81,82 lung, 83 ovarian, 84,85 prostate, 86 pancreatic, 87 and bladder cancers 77 . Likweise, Cheng et al developed a fluorescent QD‐containing DNA‐based three‐component method for selective MUC1 detection.…”

Section: Qd‐apt Conjugates For Cancer Managementmentioning

confidence: 99%

See 1 more Smart Citation

Aptamer‐functionalized quantum dots as theranostic nanotools against cancer and bacterial infections: A comprehensive overview of recent trends

Davodabadi

Mirinejad

Fathi-karkan

et al. 2023

Biotechnology Progress

View full text Add to dashboard Cite

Aptamers (Apts) are synthetic nucleic acid ligands that can be engineered to target various molecules, including amino acids, proteins, and pharmaceuticals. Through a series of adsorption, recovery, and amplification steps, Apts are extracted from combinatorial libraries of synthesized nucleic acids. Using aptasensors in bioanalysis and biomedicine can be improved by combining them with nanomaterials. Moreover, Apt‐associated nanomaterials, including liposomes, polymeric, dendrimers, carbon nanomaterials, silica, nanorods, magnetic NPs, and quantum dots (QDs), have been widely used as promising nanotools in biomedicine. Following surface modifications and conjugation with appropriate functional groups, these nanomaterials can be successfully used in aptasensing. Advanced biological assays can use Apts immobilized on QD surfaces through physical interaction and chemical bonding. Accordingly, modern QD aptasensing platforms rely on interactions between QDs, Apts, and targets to detect them. QD‐Apt conjugates can be used to directly detect prostate, ovarian, colorectal, and lung cancers or simultaneously detect biomarkers associated with these malignancies. Tenascin‐C, mucin 1, prostate‐specific antigen, prostate‐specific membrane antigen, nucleolin, growth factors, and exosomes are among the cancer biomarkers that can be sensitively detected using such bioconjugates. Furthermore, Apt‐conjugated QDs have shown great potential for controlling bacterial infections such as Bacillus thuringiensis, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Campylobacter jejuni, Staphylococcus aureus, and Salmonella typhimurium. This comprehensive review discusses recent advancements in the design of QD‐Apt bioconjugates and their applications in cancer and bacterial theranostics.

show abstract

A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research

Cited by 9 publications

References 45 publications

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Altered Glycosylation in Progression and Management of Bladder Cancer

Aptamer‐functionalized quantum dots as theranostic nanotools against cancer and bacterial infections: A comprehensive overview of recent trends

Contact Info

Product

Resources

About